PL3989961T3 - Farmaceutycznе skojarzenie związku artemizyninowego, kwasu 5-aminolewulinowego lub kwasu metylo-5-aminolewulinowego i środka chemioterapeutycznego - Google Patents

Farmaceutycznе skojarzenie związku artemizyninowego, kwasu 5-aminolewulinowego lub kwasu metylo-5-aminolewulinowego i środka chemioterapeutycznego

Info

Publication number
PL3989961T3
PL3989961T3 PL21705541.7T PL21705541T PL3989961T3 PL 3989961 T3 PL3989961 T3 PL 3989961T3 PL 21705541 T PL21705541 T PL 21705541T PL 3989961 T3 PL3989961 T3 PL 3989961T3
Authority
PL
Poland
Prior art keywords
aminolevulinic acid
methyl
chemotherapeutic agent
pharmaceutical combination
artemisinin compound
Prior art date
Application number
PL21705541.7T
Other languages
English (en)
Polish (pl)
Inventor
Ulrich Elling
Josef Martin Penninger
Original Assignee
Jlp Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jlp Health Gmbh filed Critical Jlp Health Gmbh
Publication of PL3989961T3 publication Critical patent/PL3989961T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PL21705541.7T 2020-02-19 2021-02-18 Farmaceutycznе skojarzenie związku artemizyninowego, kwasu 5-aminolewulinowego lub kwasu metylo-5-aminolewulinowego i środka chemioterapeutycznego PL3989961T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20158341.6A EP3868372A1 (en) 2020-02-19 2020-02-19 A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer
PCT/EP2021/054039 WO2021165405A1 (en) 2020-02-19 2021-02-18 A pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent

Publications (1)

Publication Number Publication Date
PL3989961T3 true PL3989961T3 (pl) 2024-04-08

Family

ID=69779738

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21705541.7T PL3989961T3 (pl) 2020-02-19 2021-02-18 Farmaceutycznе skojarzenie związku artemizyninowego, kwasu 5-aminolewulinowego lub kwasu metylo-5-aminolewulinowego i środka chemioterapeutycznego

Country Status (15)

Country Link
US (1) US20230121771A1 (cg-RX-API-DMAC7.html)
EP (2) EP3868372A1 (cg-RX-API-DMAC7.html)
JP (1) JP7719787B2 (cg-RX-API-DMAC7.html)
KR (1) KR102988319B1 (cg-RX-API-DMAC7.html)
CN (1) CN114786661A (cg-RX-API-DMAC7.html)
AU (1) AU2021222339B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022014692A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165208A1 (cg-RX-API-DMAC7.html)
DK (1) DK3989961T3 (cg-RX-API-DMAC7.html)
ES (1) ES2972799T3 (cg-RX-API-DMAC7.html)
FI (1) FI3989961T3 (cg-RX-API-DMAC7.html)
IL (1) IL294856A (cg-RX-API-DMAC7.html)
PL (1) PL3989961T3 (cg-RX-API-DMAC7.html)
PT (1) PT3989961T (cg-RX-API-DMAC7.html)
WO (1) WO2021165405A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220184234A1 (en) * 2020-11-30 2022-06-16 Sonalasense, Inc. Metabolic targeting of low grade tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000051I1 (de) 1995-03-10 2007-01-04 Photocure Asa Ester der 5-Aminolevulins{ure als Mittel zur Photosensibillisierung in der Chemotherapie
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
TWI482621B (zh) 2009-12-23 2015-05-01 Sigma Tau Ind Farmaceuti 青蒿素基藥物與其他化學治療劑的抗癌組合物
JP2011225471A (ja) 2010-04-16 2011-11-10 Univ Of Tsukuba 抗癌剤の効果増強剤
US10925963B2 (en) * 2015-06-22 2021-02-23 Washington University Combination artemisinin and chemiluminescent photodynamic therapy and uses therefor
CN105963244A (zh) 2016-01-15 2016-09-28 赵鸣 注射用青蒿琥酯制剂及其应用
CN106527586B (zh) * 2016-11-04 2019-09-06 吉林省北方医药有限责任公司 一种移动终端设备
CN108570089B (zh) * 2017-04-28 2019-10-29 云白药征武科技(上海)有限公司 双氢青蒿素-甾体结合物及其制备方法和应用
GB201800736D0 (en) * 2018-01-17 2018-02-28 St Georges Hospital Medical School Combination therapy for treatment of leukemia
CN108635581A (zh) * 2018-05-23 2018-10-12 昆药集团股份有限公司 一种组合物及其在制备治疗肿瘤的药物中的应用

Also Published As

Publication number Publication date
PT3989961T (pt) 2024-02-26
WO2021165405A1 (en) 2021-08-26
DK3989961T3 (da) 2024-01-29
JP2023514426A (ja) 2023-04-05
AU2021222339B2 (en) 2026-05-21
IL294856A (en) 2022-09-01
JP7719787B2 (ja) 2025-08-06
BR112022014692A2 (pt) 2022-09-20
KR102988319B1 (ko) 2026-07-07
CN114786661A (zh) 2022-07-22
EP3868372A1 (en) 2021-08-25
US20230121771A1 (en) 2023-04-20
EP3989961A1 (en) 2022-05-04
FI3989961T3 (fi) 2024-02-14
AU2021222339A1 (en) 2022-07-28
KR20220143097A (ko) 2022-10-24
CA3165208A1 (en) 2021-08-26
EP3989961B1 (en) 2023-11-22
ES2972799T3 (es) 2024-06-17

Similar Documents

Publication Publication Date Title
MA53388A (fr) Inhibiteurs d&#39;inflammasome nlrp3
EP3400218A4 (en) COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE
IL312076A (en) Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof
EP4129087A4 (en) MASKING AGENT
MY201325A (en) Substituted nitrogen containing compounds
EP4616922A4 (en) WATER POLO BALL
EP4274655A4 (en) COMBINATION BALLOON CATHETER
EP4291556C0 (en) HYDROXYHETEROCYCLOALKANE-CARBAMOYL DERIVATIVES
EP4161900A4 (en) Cannabidiolic acid (cbda) derivatives and uses thereof
EP4434989A4 (en) Heterocyclic inhibitor of methionine adenosyltransferase 2A
EP4216936A4 (en) INHALATE PDE-V INHIBITOR MEDICINES
MA71689A (fr) Inhibiteurs de l&#39;inflammasome nlrp3
CY1123728T1 (el) (2r,4r)-5-(5&#39;-χλωρο-2&#39;-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
EP4042897C0 (de) Schnallenbauteil
EP4251630A4 (en) Sulfonyl urea nlrp3 inflammasome inhibitors
EP4159839A4 (en) ANTIVIRAL AGENT
EP4157297A4 (en) MEDICATIONS FOR RESPIRATORY TRACT
DK4118091T3 (da) Immunomodulerende urea-azalider
EP4583953C0 (en) INTERMITTENT CATHETER
PT3989961T (pt) Uma combinação farmacêutica de um composto de artemisinina, ácido 5-aminolevulínico ou ácido metil-5-aminolevulínico e um agente quimioterapêutico
IL305851A (en) Preparation of 2-chloro-4-fluoro-5-nitrobenzoic acid
EP4331583A4 (en) Blood carnitine increasing agent
UY31058A1 (es) Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
EP4151230A4 (en) ANTIVIRAL AGENT
EP4370109A4 (en) SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) DRUGS, CONJUGATES AND NANOPARTICLES, AND METHODS OF USE THEREOF